Key result
GLP-1 RAs did not significantly reduce AF incidence in RCTs (OR 0.94, p=0.23), but observational studies showed a modest AF risk reduction (HR 0.93, p=0.001).
Why the study?
GLP-1 RAs have cardiovascular benefits, but their potential role in AF prevention remains uncertain due to inconsistent clinical data.
Do GLP-1 RAs reduce the incidence of atrial fibrillation compared to placebo or other antidiabetic agents?
Do GLP-1 RAs reduce the incidence of atrial fibrillation compared to placebo or other antidiabetic agents?
Current RCT evidence does not support a significant reduction in atrial fibrillation incidence with GLP-1 receptor agonists, despite modest associations seen in observational data.
Background Atrial fibrillation (AF) is a growing global public health burden associated with significantly morbidity and healthcare costs. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated substantial cardiovascular benefits, yet their potential role in AF prevention remains uncertain. While experimental studies suggest GLP-1 RAs may exert antiarrhythmic effects, clinical data on their impact on AF incidence are inconsistent. This systematic review and meta-analysis aim to evaluate the association between GLP-1 RAs and AF risk compared to placebo and other antidiabetic agents. Purpose To assess whether GLP-1 RAs influence the incidence and burden of AF compared to placebo or other antidiabetic agents. This addresses a critical gap in cardiovascular risk management strategies. Methods A literature search was conducted across PubMed, Embase, MEDLINE, Cochrane Library and ClinicalTrials.gov. 30 randomised controlled trials (RCTs) and 8 retrospective observational studies comparing GLP-1 RAs to placebo or other non-GLP-1 RA drugs with reported AF outcomes were included in this analysis. The primary outcome measure was the incidence of AF after a minimum follow-up of 24 weeks. A random-effects meta-analysis was performed to calculate pooled odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI). Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) tool for the RCTs and the Newcastle-Ottawa Scale (NOS) for the observational studies. Results The meta-analysis of RCTs found no overall higher risk of atrial arrhythmias with GLP-1 RAs compared to placebo (OR: 0.94 [95% CI: 0.86–1.04], p = 0.23). Observational studies suggested a modest association with lower AF risk (HR: 0.93 [95% CI: 0.89–0.97], p = 0.001). Significant heterogeneity was observed in the observational data (I² = 83%). Subgroup analysis suggested a potential benefit with semaglutide, but this did not reach statistical significance. Funnel plot analyses showed no major publication bias. Conclusion This meta-analysis demonstrates that GLP-1 RAs do not significantly reduce the incidence of AF. While the observational data suggest a moderate reduction in AF incidence. Further research is required to determine whether specific GLP-1 RAs, such as semaglutide, may exert beneficial AF-related effects. Future RCTs with AF as a primary endpoint are needed to clarify the potential role of GLP-1 RAs in AF prevention and management. The findings support the continued prioritisation of established AF prevention strategies and signpost the need for future research surrounding GLP-1 RAs.
No takes yet. Share an insight, caveat, or question.
Krishnarjun Banerjee (2025) studied this question. GLP-1 RAs did not significantly reduce AF incidence in RCTs (OR 0.94, p=0.23), but observational studies showed a modest AF risk reduction (HR 0.93, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: